Scholars Central

Conference abstractPublished 19 Nov 2012

Modified HIV tat peptide with cationic lipids as a non-viral vector for efficient gene delivery in vitro and in vivo

Authors: Seiichi Yamano

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

To improve the efficiency of non-viral gene delivery, we combined the lipid FuGENE HD (FH) with the HIV Tat peptide sequence modified with histidine and cysteine residues (mTat), and evaluated whether mTat/FH could be used for gene delivery in vitro and in vivo . mTat/FH transfection was evaluated by luciferase expression plasmid in five cell types compared to five commercial reagents. Cytotoxicity, the zeta potentials, and size of mTat/FH and each component individually were determined, and transfection efficiency at different temperatures was examined. The endocytosis mechanism of mTat/FH/ DNA complexes was investigated. To examine the ability of mTat/FH in vivo , luciferase expression was measured using a real- time bioluminescence imaging system after intramuscular administration of mTat/FH/DNA. mTat/FH produced significant improvement in transfection efficiency of all cell lines with little cytotoxicity when compared to mTat alone, FH alone, or five commercial reagents. The zeta potential of mTat/FH/DNA was significantly higher compared to FH, mTat, or their DNA combination. The particle size of the FH/DNA complex was significantly reduced by addition of mTat. It was revealed that temperature-dependent and caveolae-mediated endocytosis of mTat/FH transfection was utilized. The results of in vivo study demonstrated the animals intramuscularly administered with mTat/FH/DNA had significantly higher and longer luciferase expression than those with mTat/DNA or FH/DNA. These findings demonstrated a combination of mTat with lipids improved transfection efficiency in several cell lines and it enabled efficient gene delivery in vivo. It makes mTat/FH a highly interesting non-viral gene vector for the future utilization, both in vitro and in vivo.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Genetic Syndromes & Gene Therapy
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Seiichi Yamano”